ACW announces positive XanaMIA results for Xanamem
Filed with ASX · · 4 pages · English
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- Letter to Shareholders & Notice of General Meeting
- Actinogen Medical: ACW CEO Presents at European Life Sciences Conference
- Appendix 4D & Half-Year Financial Statements
- Actinogen XanaMIA Part A trial results expected in April
- Actinogen appoints XanaFX Phase 2 trial manager
Later from Actinogen Medical
- ACW positive XanaMIA results webcast slide presentation
- Quarterly Activity Report & Appendix 4C
- Actinogen prioritizes Alzheimers Disease & Depression
- Actinogen trial results & strategic update presentation
- ACW announces Phase 2 trial designs for AD & MDD
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical